Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  AMAG Pharmaceuticals, Inc.    AMAG

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/05/2017 12/06/2017 12/07/2017 12/08/2017 12/11/2017 Date
14.35(c) 13.95(c) 14.1(c) 14.4(c) 14.425(c) Last
709 352 659 672 664 795 680 441 791 115 Volume
+3.99% -2.79% +1.08% +2.13% +0.17% Change
More quotes
Financials ($)
Sales 2017 616 M
EBIT 2017 -82,7 M
Net income 2017 -195 M
Debt 2017 518 M
Yield 2017 -
Sales 2018 504 M
EBIT 2018 27,7 M
Net income 2018 -110 M
Debt 2018 560 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 1,67x
EV / Sales2018 2,12x
Capitalization 509 M
More Financials
Company
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia.It focuses on the development and commercialization of Feraheme injection for intravenous or IV, use to treat iron... 
Sector
Pharmaceuticals
Calendar
02/13Earnings Release
More about the company
Surperformance© ratings of AMAG Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on AMAG PHARMACEUTICALS, INC.
12/01 AMAG PHARMACEUTICALS,INC. (NASDAQ : AMAG) Files An 8-K Departure of Directors or..
11/30 AMAG PHARMACEUTICALS INC. : Change in Directors or Principal Officers, Financial..
11/09 AMAG PHARMACEUTICALS : Announces Autologous Cord Blood Cells Improve Motor Funct..
11/09 AMAG PHARMACEUTICALS : Hypophosphatemia Data From AMAG Phase 3 Trial Presented a..
11/08 AMAG Pharmaceuticals to Present at Upcoming Investor Conference
11/08 AMAG Announces Autologous Cord Blood Cells Improve Motor Function in Some Chi..
11/08 AMAG PHARMACEUTICALS : Announces Third Quarter 2017 Financial Results and Busine..
11/06 Hypophosphatemia Data From AMAG Phase 3 Trial Presented at the American Socie..
11/02 AMAG PHARMACEUTICALS : reports 3Q loss
11/02 AMAG PHARMACEUTICALS INC. : Results of Operations and Financial Condition, Finan..
More news
Sector news : Pharmaceuticals - NEC
11:03aDJMERCK : Appoints Allan Gabor as Managing Director in China
08:42aDJGLAXOSMITHKLINE : Encouraged By Blood-Cancer Drug Study
07:32aDJSANOFI : Receives U.S. FDA Approval for Insulin Injection Admelog
12:56a Monsanto offers cash to U.S. farmers who use controversial chemical
12/11 ASTRAZENECA : GSK's new pharma head on lookout for cancer deals to boost pipelin..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/07 Premarket analyst action - healthcare
11/30 YOUR DAILY PHARMA SCOOP : Valeant's B+L In India, TXMD's NDA Resubmission, Melin..
11/14 Antares Pharma On Sale
11/10 The Sum Of All Fears For This Small Pharma
11/05 AMAG Pharmaceuticals, Inc. 2017 Q3 - Results - Earnings Call Slides
Chart AMAG PHARMACEUTICALS, INC.
Duration : Period :
AMAG Pharmaceuticals, Inc. Technical Analysis Chart | AMAG | US00163U1060 | 4-Traders
Technical analysis trends AMAG PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 17,7 $
Spread / Average Target 23%
EPS Revisions
Managers
NameTitle
William K. Heiden President, Chief Executive Officer & Director
Gino Santini Chairman
Edward H. Myles Chief Financial Officer, Treasurer & Senior VP
Julie Krop Chief Medical Officer & SVP-Regulatory Affairs
Nathan McBride Chief Information Officer & Senior VP-Innovation
Sector and Competitors
1st jan.Capitalization (M$)
AMAG PHARMACEUTICALS, INC.-59.48%509
JOHNSON & JOHNSON21.53%379 175
NOVARTIS12.15%218 773
PFIZER9.30%215 837
ROCHE HOLDING LTD.3.40%209 423
MERCK AND COMPANY-6.96%153 659